Business
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
2025: strong sales and EPS growth.Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3% at CER1 and business earnings per share (EPS)2 of €1.53 Pharma launches increased sales by 49.4%, reaching €1.1 billion, primarily driven by Ayvakit and ALTUVIIIODupixent sales increased by 32.2% to €4.2 billion, a strong end to the yearVaccines sales decreased by 2.5% to €2.0 billion, with influenza performing better than anticipatedResearch and Development expenses re
About this update from Sanofi Sa
[{"type":"image","alt":"Sanofi Winthrop Industrie","displaySize":"","headline":null,"caption":"Sanofi Winthrop Industrie","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/njIuMc8eT.GfUOY8hGPCUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137","width":300,"height":84}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"2025: strong sales and EPS growth.Continued profitable growth expected in 2026","length":79,"tagName":"p"},{"type":"text","content":"Paris, January 29, 2026","length":23,"tagName":"p"},{"type":"text","content":"Q4 sales growth of 13.3% at CER1 and business earnings per share (EPS)2 of €1.53","length":80,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pharma launches increased sales by 49.4%, reaching €1.1 billion, primarily driven by Ayvakit and ALTUVIIIO","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Dupixent sales increased by 32.2% to €4.2 billion, a strong end to the year","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Vaccines sales decreased by 2.5% to €2.0 billion, with influenza performing better than anticipated","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Research and Development expenses reached €2.3 billion, up by 6.6%","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Selling, general and administrative expenses reached €2.7 billion, up by 9.6%, supporting launches","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Business EPS was €1.53, up by 26.7% at CER; 16.8% at actual exchange rates, delivering profitable growth; IFRS EPS -€0.66","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":565,"olType":false},{"type":"text","content":"Pipeline progress","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ten regulatory approvals across immunology, rare diseases, and other","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive phase 3 readouts: amlitelimab program in AD (COAST 2, SHORE) and Dupixent in AFRSTolebrutinib in PPMS did not meet the primary endpoint","...